Skip to main content

EXEL

Stock
Health Care
Biotechnology

Performance overview

EXEL Price
Price Chart

Forward-looking statistics

Beta
0.63
Risk
34.99%

Detailed forecast

[disclaimer]

Individual forecast components (weighted-sum)

Company Profile

Exelixis is a biopharmaceutical firm that discovers, develops, and commercializes treatments for cancer. Its lead molecule, cabozantinib, is indicated for the treatment of patients with metastatic medullary thyroid cancer under the name Cometriq and for the treatment of kidney and liver cancer under the name Cabometyx. Exelixis and its partner Roche have also brought Cotellic to market for the treatment of melanoma.

Company info

SectorHealth Care
IndustryBiotechnology
Employees1K
Market cap$6.4B

Fundamentals

Enterprise value$11.2B
Revenue$2.3B
Revenue per employee—
Profit margin27.99%
Debt to equity8.78

Security info

ExchangeNASDAQ
Type of shareCommon Stock
Earnings per share (EPS)$2.19
Dividend per share—
Revenue per share$8.08
Avg trading volume (30 day)$151M
Avg trading volume (10 day)$218M
Put-call ratio—

Macro factor sensitivity

Growth+1.7
Credit+1.4
Liquidity+0.5
Inflation+0.6
Commodities+0.9
Interest Rates-1.2

Valuation

Dividend yield0.00%
PEG Ratio27.15
Price to sales5.47
P/E Ratio27.15
Enterprise Value to Revenue4.86
Price to book5.96

Upcoming events

Next earnings dayOctober 30, 2024
Next dividend day—
Ex. dividend day—

News

Why Exelixis (EXEL) is a Top Momentum Stock for the Long-Term

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further than the Zacks Style Scores.

Zacks Investment Research (July 10, 2025)
EXEL or ARGX: Which Is the Better Value Stock Right Now?

Investors with an interest in Medical - Biomedical and Genetics stocks have likely encountered both Exelixis (EXEL) and argenex SE (ARGX). But which of these two companies is the best option for those looking for undervalued stocks?

Zacks Investment Research (July 3, 2025)
5 Biotech Stocks to Buy in 2025 Amid Uncertain Macroenvironment

New drug approvals and encouraging pipeline progress should maintain momentum in the Zacks Biomedical and Genetics industry despite the uncertain macroeconomic environment. A strong portfolio and solid pipeline progress position EXEL, VRNA, ALKS, KNSA and IMCR well in this volatile sector.

Zacks Investment Research (July 2, 2025)
Buy 5 High-Flying Non-Tech Nasdaq-Listed Stocks of H1 to Gain in H2

Nasdaq is flat in first-half 2025, but SFM, RGLD, TRI, WWD and EXEL are soaring, each up over 20% and primed for the second half.

Zacks Investment Research (June 24, 2025)

Unlock Personalized Financial Tools

All our core financial tools are completely free. Create an account to save your research, get personalized recommendations, and enjoy unlimited access.

Save research to draft portfolios
Get personalized recommendations
Access unlimited tool usage
Sign up for free